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Abstract
Background Nutrition screening on admission to hospital is mandated in many countries, but to date, there is no consensus
on which tool is optimal in the oncology setting. Wasting conditions such as cancer cachexia (CC) and sarcopenia are common
in cancer patients and negatively impact on outcomes; however, they are often masked by excessive adiposity. This study
aimed to inform the application of screening in cancer populations by investigating whether commonly used nutritional
screening tools are adequately capturing nutritionally vulnerable patients, including those with abnormal body composition
phenotypes (CC, sarcopenia, and myosteatosis).
Methods A prospective study of ambulatory oncology outpatients presenting for chemotherapy was performed. A detailed
survey incorporating clinical, nutritional, biochemical, and quality of life data was administered. Participants were screened for
malnutrition using the Malnutrition Universal Screening Tool (MUST), Malnutrition Screening Tool (MST), and the Nutritional
Risk Index (NRI). Computed tomography (CT) assessment of body composition was performed to diagnose CC, sarcopenia, and
myosteatosis according to consensus criteria.
Results A total of 725 patients (60% male, median age 64 years) with solid tumours participated (45% metastatic disease).
The majority were overweight/obese (57%). However, 67% were losing weight, and CT analysis revealed CC in 42%, sarcopenia
in 41%, and myosteatosis in 46%. Among patients with CT-identiﬁed CC, the MUST, MST, and NRI tools categorized 27%, 35%,
and 7% of them as ‘low nutritional risk’, respectively. The percentage of patients with CT-identiﬁed sarcopenia and
myosteatosis that were categorised as ‘low nutritional risk’ by MUST, MST and NRI were 55%, 61%, and 14% and 52%,
50%, and 11%, respectively. Among these tools, the NRI was most sensitive, with scores <97.5 detecting 85.8%, 88.6%, and
92.9% of sarcopenia, myosteatosis, and CC cases, respectively. Using multivariate Cox proportional hazards models, NRI
score < 97.5 predicted greater mortality risk (hazard ratio 1.8, conﬁdence interval: 1.2–2.8, P = 0.007).
Conclusions High numbers of nutritionally vulnerable patients, with demonstrated abnormal body composition phenotypes
on CT analysis, were misclassiﬁed by MUST and MST. Caution should be exercised when categorizing the nutritional risk of
oncology patients using these tools. NRI detected the majority of abnormal body composition phenotypes and independently
predicted survival. Of the tools examined, the NRI yielded the most valuable information from screening and demonstrated
usefulness as an initial nutritional risk grading system in ambulatory oncology patients.
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Introduction
Cancer-related malnutrition is a term that encompasses a
range of altered nutritional states including cancer-induced
weight loss, sarcopenia, myosteatosis, pre-cachexia, and
cancer cachexia (CC). The rate of malnutrition can vary
greatly depending on tumour site and stage; however, it is
estimated to affect between 8% and 85% of cancer
patients.1–4 Identiﬁcation of malnutrition is critical as it
negatively impacts on prognosis and has been associated
with a range of adverse clinical outcomes.5–13 Severe
malnutrition is independently associated with mortality, with
an estimated 20–30% of cancer deaths attributable to
malnutrition.14,15 Abnormal body composition phenotypes
such as sarcopenia, myosteatosis, and cachexia are of partic-
ular importance in the oncology setting as poor muscularity
is strongly associated with negative clinical outcomes,
however can often be masked by the excessive adiposity
that is so common among newly diagnosed cancer
patients.16–18 Timely detection is essential to ensure that
tailored nutritional support can be implemented early when
intervention is most effective, before an irreversible, refrac-
tory state takes hold.9
Computed tomography (CT) assessment is the gold
standard method of body composition analysis and diagnosis
of abnormal body composition phenotypes.16,19 CT analysis is
particularly useful in this setting, as CT scans are routinely
performed during diagnosis and staging of the disease. CT
assessment of body composition takes approximately
20 min per scan in trained personnel. Unless automation of
CT analysis becomes widely available in the clinical setting,
routine analysis for all oncology patients is currently not
feasible. As a result, it is essential that time-efﬁcient,
accurate, and effective methods of screening the nutritional
risk of patients are available. Effective screening would allow
clinicians to triage patients, referring those that are nutrition-
ally vulnerable for urgent nutritional assessment, including
assessment of body composition, and ensure timely, targeted
interventions are implemented.
Despite the critical importance of early diagnosis and inter-
vention, malnutrition is thought to be widely underdiagnosed
in the oncology setting.20–22 In the USA, the Joint Commission
has mandated universal screening and assessment of malnu-
trition in hospitalized patients within 24 h of admission since
1995.23,24 However, no consensus exists on the optimal
nutritional screening tool for the detection of malnutrition,
particularly the screening of oncology patients in either the
inpatient or outpatient setting.
To our knowledge, no studies have been performed in
oncology patients to assess whether existing nutritional
screening tools are correctly capturing forms of cancer-
related malnutrition that would otherwise require CT scan
to detect, or whether these tools can be used to predict
adverse clinical outcomes. Therefore, the aim of this study
was to assess whether Malnutrition Universal Screening Tool
(MUST), Malnutrition Screening Tool (MST), and Nutritional
Risk Index (NRI) successfully detect nutritionally vulnerable
oncology patients, including those with abnormal body
composition phenotypes such as sarcopenia, myosteatosis,
and cachexia.
Materials and methods
Ethical approval for this study was granted by the Clinical
Research Ethics Committee of the Cork Teaching Hospitals.
This study was performed as part of a large prospective
investigation conducted at two university teaching hospitals
in Cork, Ireland, between 2012 and 2016. All adult
(≥18 years) ambulatory patients, diagnosed with malignant
solid tumours, presenting for chemotherapy were eligible
for inclusion. Signed, informed consent was obtained from
all participants, and patients were assessed during the ﬁrst
cycle of chemotherapy (or other systemic anti-cancer
therapy).
Collection of clinical data
A detailed questionnaire was disseminated by the research
team and included questions relating to demographic data,
oncologic data, smoking and alcohol intake, weight loss
history, and appetite. Medical history, histopathological
diagnosis, performance status, details of oncologic therapy,
dates of death, and any missing data were obtained through
a chart review.
Collection of nutritional data
Nutritional parameters were obtained from both the study
questionnaire and through a chart review. Body weight and
height were measured to within 0.1 kg and 0.5 cm, respec-
tively. Body mass index (BMI) was calculated and categorized
according to the World Health Organization’s classiﬁcation of
BMI.25 Patient-reported pre-illness weight and the time
frame of any weight loss were recorded. The degree of
weight loss was classiﬁed according the Blackburn criteria
for weight loss.26 CC, a multifactorial syndrome deﬁned by
an ongoing loss of skeletal muscle mass (with or without loss
of fat mass) that cannot be fully reversed by conventional
nutritional therapy and leads to progressive functional
impairment, was diagnosed using the international consensus
deﬁnition.9 Pre-cachexia was deﬁned using the diagnostic
criteria outlined by the European Society of Clinical Nutrition
and Metabolism Special Interest Group for ‘cachexia–
anorexia in chronic wasting diseases’.27 Pre-cachexia includes
patients with a chronic disease, small weight loss, a chronic
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or recurrent systemic inﬂammatory response, and anorexia.
Anorexia was assessed using responses from the anorexia
question within the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life Questionnaire
(QLQ) C30. ‘Have you lacked appetite’, which has a four choice
response; 1 = not at all, 2 = a little, 3 = a lot, and 4 = very much.
If patients give a response of 2, 3, or 4, they were classiﬁed as
demonstrating some degree of anorexia. Systemic inﬂamma-
tion was categorized as a serum C-reactive protein level of
≥5 mg/L, which is the upper limit for serum C-reactive protein
in the institution where the study was performed.
Nutritional data gathered as part of the study question-
naire were used to assess patients’ nutritional risk using
three commonly used malnutrition screening tools: MUST,28
MST,29 and NRI.30 All three tools can be completed in
2–3 min and incorporate information that is readily available
in patients receiving chemotherapy. MUST generates scores
on the basis of BMI, unplanned weight loss, and acute
disease effect, with the overall score then allowing
categorization into three ‘at risk’ levels: low risk (MUST score
0), medium risk (MUST score 1), and high risk (MUST score
2) groups. MST investigates risk of malnutrition on the basis
of unintentional weight loss, the extent of weight loss that
has occurred and reduced oral intake secondary to anorexia.
A total score of 0–7 is generated, with a score of 0 or 1
indicating a patient that is not at risk of malnutrition, while
a score of ≥2 represents a patient at risk of malnutrition.
NRI is a screening tool based on serum albumin and weight
loss. A score is calculated for each patient using the
formula: 1.519 (serum albumin; g/dL) + 41.7 (current
weight/usual weight).30 An NRI score of >100 indicates
that the patient is not malnourished. An NRI score of
97.5–100 denotes mild malnourishment, 83.5–97.5 indicates
moderate malnourishment, while <83.5 indicates severe
malnourishment.
Body composition analysis by computed
tomography
Computed tomography scans, performed routinely as part of
diagnostic investigations, were used to analyse body composi-
tion at baseline. Cross-sectional area of muscle was analysed
in contrast-enhanced CT scans at the level of the third lumbar
vertebra (L3), using OsiriX software (Version 5.0) (Pixmeo,
Geneva, Switzerland), as previously described.31,32 Muscle
area was normalized for stature by dividing by height in
metres squared and was then reported as skeletal muscle
index (cm2/m2). Skeletal muscle density was assessed by
computing the mean radiation attenuation of the entire
muscle area at L3 in contrast enhanced CT scans, expressed
in Hounsﬁeld units. Sarcopenia is deﬁned as appendicular
skeletal muscle mass greater than 2 SD below the mean of a
healthy, reference population, while myosteatosis is
characterized by low radiation attenuation secondary to in-
creased levels of intermuscular and intramuscular fat.
Sarcopenia and myosteatosis were diagnosed using previ-
ously deﬁned sex-speciﬁc and BMI-speciﬁc cut-off points, de-
vised from a cancer population.18
Statistical analysis
Statistical analysis was performed by SPSS (version 22) for
Windows (IBM Corp. Released 2013. IBM SPSS Statistics for
Windows, Version 22.0. Armonk, NY: IBM Corp.). Preliminary
analyses were carried out to ensure that the assumptions of
normality, linearity, or homoscedasticity were not violated. χ2
tests were used to compare categorical variables. Receiver
operating characteristic curves were generated to assess the
diagnostic performance of screening tools, with the area
under the curve (AUC) indicating the accuracy of the tool. The
Hosmer and Lemeshow’s classiﬁcation of AUC values was used
to classify AUC scores.33 Multivariate Cox proportional hazards
models were used to estimate covariate adjusted hazard ratios
(HRs). All statistical tests were two-sided, and exact P-values
are reported. Signiﬁcance was taken at the level of P < 0.05.
Results
Demographic, clinical, and nutritional
characteristics of study cohort
In total, 725 oncology outpatients, of mixed cancer types,
receiving chemotherapy provided signed informed consent.
The demographic, clinical, and nutritional characteristics of
the cohort, according to sex, are displayed in Table 1.
Colorectal cancer was most common, representing close to
one-third of the cohort (32.3%), followed by gastro-
oesophageal (15.9%) and respiratory malignancies (11.4%).
Metastatic disease was present in 45% of the cohort, with
the liver being the most common site of metastases. The
cohort had a good level of functioning, with 79.2% having
an Eastern Cooperative Oncology Group (ECOG) score of
0–1. The majority had a BMI in the overweight/obese range
(55.6%), while 4.4% had a BMI in the underweight category.
At screening, CC was identiﬁed in 41.5% of the cohort. CC oc-
curred most frequently in hepatobillary (64%), oesophageal
(60%), and gynae cancers (58%). Of patients that were diag-
nosed with CC, 137 (37.2% of cachectic patients) had either
no weight loss or limited weight loss and were diagnosed
by ‘Step 3’ or by CT analysis of muscle mass alone. Overall,
sarcopenia was present in 41% of the cohort and was most
prevalent in patients with hepatobillary (53%) and breast can-
cer (52%). Myosteatosis was identiﬁed in 45.5% of partici-
pants and was most prevalent in those with respiratory
(60.7%) and gynaecological (53.7%) malignancies.
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Nutrition risk assessed by Malnutrition Universal
Screening Tool, Malnutrition Screening Tool, and
Nutritional Risk Index
Table 2 outlines the nutritional risk of patients when assessed
using nutritional screening tools. MUST identiﬁed 40.8% of
the cohort as being at a moderate or high risk of malnutrition
(MUST score ≥ 1). MST deemed 41.2% of the cohort to be at
risk of malnutrition (MST score ≥ 2), while 90% of patients
were classiﬁed as having some degree of malnutrition, ac-
cording to NRI (NRI score of <100).
Comparing body composition analysis by
computed tomography to nutrition risk assessment
by nutrition screening tools
Table 3 displays the proportion of each of the abnormal body
composition phenotypes, diagnosed by gold standard
methods that were given a score indicative of no/low nutri-
tional risk by the screening tool. MUST classiﬁed 55% of true
sarcopenia cases, as diagnosed using gold standard methods,
as being at a low risk of malnutrition. MUST misclassiﬁed the
highest number of both myosteatosis (52%) and pre-cachexia
Table 1 Demographic, clinical, and nutritional characteristics according to sex
Male n = 433 (59.7%) Female n = 292 (40.3%) Overall n = 725
Age, median (IQR) 65.3 (57.4–71.9) 62.2 (52.9–70.0) 64.3 (55.9–71.0)
Age > 65 years, n (%) 221 (51) 128 (43.8) 349 (48.1)
Treatment plan, n (%)
Chemotherapy only 191 (44.1) 157 (53.8) 348 (48)
Chemotherapy and surgery 132 (30.5) 76 (26) 208 (28.7)
Chemo-radiotherapy and surgery 49 (11.3) 39 (13.4) 88 (12.1)
Chemo-radiotherapy 38 (8.8) 11 (3.8) 49 (6.8)
Unknown 23 (5.3) 9 (3.0) 32 (4.4)
Metastasis present, n (%) 192 (44.3) 134 (45.9) 326 (45)
Weight change since diagnosis n (%)
Weight loss 297 (68.6) 190 (65.1) 487 (67.2)
Weight stable 52 (12.0) 38 (13.0) 90 (12.4)
Weight gain 84 (19.4) 64 (21.9) 148 (20.4)
Weight loss (%) [mean (±SD)] 6.3 (±7.3) 7.3 (±8.5) 6.7 (±7.8)
>10% weight loss in past 6 months n (%) 75 (17.3) 61 (20.9) 136 (18.8)
BMI (kg/m2) n (%)
Underweight (BMI <18.5 kg/m2) 10 (2.3) 22 (7.5) 32 (4.4)
Healthy weight (BMI 18.5–24.9 kg/m2) 156 (36.0) 134 (45.9) 290 (40.0)
Overweight (BMI 25–29.9 kg/m2) 185 (42.7) 83 (28.4) 268 (37.0)
Obese (BMI ≥30 kg/m2) 82 (19) 53 (18.2) 135 (18.6)
BMI (kg/m2) mean (±SD) 26.3 (±4.3) 25.1 (±5.1) 25.8 (±4.6)
Cancer cachexia n (%) 192 (44.3) 109 (37.3) 301 (41.5)
Pre-cachexiaa n (%) 18 (5.7) 12 (6.0) 30 (5.8)
Sarcopeniab n (%) 144 (35.8) 130 (48.9) 274 (41)
Myosteatosisc n (%) 149 (40.8) 132 (52.2) 281 (45.5)
BMI, body mass index; IQR, interquartile range; SD, standard deviation.
aPre-cachexia assessed in n = 514 (male n = 315, female n = 199),
bSarcopenia measurable in n = 661 (male n = 402, female n = 266),
cMuscle density measureable in n = 618 (male n = 365, female n = 253). All percentages given for total available.
Table 2 Nutritional risk scores from Malnutrition Universal Screening Tool, Malnutrition Screening Tool, and Nutritional Risk Index
Male n = 433 (59.7%) Female n = 292 (40.3%) Overall n = 792
MUST
Score 0 (low risk) 272 (62.8) 157 (53.8) 429 (59.2)
Score 1 (moderate risk) 78 (18.0) 54 (18.5) 132 (18.2)
Score ≥ 2 (high risk) 83 (19.2) 81 (27.7) 164 (22.6)
MST
Score 0–1 (not at risk of malnutrition) 255 (58.9) 171 (58.6) 426 (58.8)
Score 2–5 (at risk of malnutrition) 178 (41.1) 121 (41.4) 299 (41.2)
NRIa
Score > 100 (not malnourished) 35 (9.9) 21 (10.3) 56 (10)
Score 97.5–100 (mild malnourishment) 37 (10.5) 23 (11.2) 60 (10.7)
Score 83.5–97.5 (moderate malnourishment) 220 (62.3) 119 (58.0) 339 (60.8)
Score < 83.5 (severe malnourishment) 61 (17.3) 42 (20.5) 103 (18.5)
MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening Tool; NRI, Nutrition Risk Index.
aNRI data available in n = 558 (male n = 353; female n = 205).
4 É. Ní Bhuachalla et al.
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12258
(57%), while MST misclassiﬁed the highest proportion of
sarcopenia (61%), CC (35%), and the presence of at least
one of the conditions (52%). Figure 1 illustrates the relation-
ship between sarcopenia diagnosed by gold standard body
composition and ‘at risk’ scores from MUST, MST, and NRI.
Of the 41% of the cohort with sarcopenia, 18.6% were cate-
gorized as moderate to high risk by MUST and 16.2% as ‘at
risk’ by MST. NRI captured a large proportion of sarcopenic
patients, highlighting 36.7% of those with sarcopenia as being
at nutritional risk. Figure 2 illustrates the relationships be-
tween CC and ‘at risk’ scores from MUST, MST, and NRI. Of
the proportion of the cohort with CC (41.5%), 30.2% were
classiﬁed as being at moderate to high risk by MUST and
26.3% as ‘at risk’ by MST. NRI detected the highest propor-
tion of cachectic patients, ﬂagging 42.1% of the cohort as at
nutritional risk.
Table 3 Prevalence of abnormal muscle mass and cancer cachexia in patients screened as ‘low risk’ using screening tools
Low risk scoring
Sarcopenia Myosteatosis Pre-cachexia Cancer cachexia Any one of these conditions
n (%) n (%) n (%) n (%) n (%)
MUST (score 0) 150 (55) 146 (52) 17 (57) 82 (27) 244 (49)
MST (score 0–1) 166 (61) 141 (50) 7 (23) 129 (35) 259 (52)
NRI (score > 97.5) 32 (14) 26 (11) 1 (3) 18 (7) 54 (13)
MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening Tool; NRI, Nutrition Risk Index.
Figure 1 The relationship between sarcopenia diagnosed by gold stan-
dard body composition analysis and Malnutrition Universal Screening
Tool (MUST) ‘high risk’ scores, Malnutrition Screening Tool (MST) ‘at risk’
scores, and Nutritional Risk Index (NRI) ‘at risk’ scores.
Sarcopenia
22.4% 18.6% 23.2%
Neither= 35.8%
Sarcopenia
24.8% 16.2% 25.6%
Neither= 33.4%
Sarcopenia 
(42.7%)
36.7% 42.9%
6.0%
Neither= 14.4%
Figure 2 The relationship between cancer cachexia diagnosed by gold
standard body composition analysis and Malnutrition Universal Screening
Tool (MUST) ‘high risk’ scores, Malnutrition Screening Tool (MST) ‘at risk’
scores, and Nutritional Risk Index (NRI) ‘at risk’ scores.
Cancer Cachexia MUST Score 1
11.3%
30.2%
10.6%
Neither= 47.6%
MST Score 2Cancer Cachexia
15.2% 26.3% 14.9%
Neither= 43.6%
NRI Score <97.5Cancer Cachexia 
3.2%
42.1% 37.1%
Neither= 17.6%
Is nutritional screening capturing hidden malnutrition in oncology patients? 5
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12258
Sensitivity and speciﬁcity of Malnutrition Universal
Screening Tool, Malnutrition Screening Tool, and
Nutritional Risk Index in detecting abnormal body
composition
The sensitivity, speciﬁcity, and total accuracy of the screening
tools in detecting abnormal body composition phenotypes
diagnosed by gold standard methods is displayed in Table 4.
Receiver operating characteristic curves were also generated
to compare the tools’ ability to detect the conditions. The
AUC for all three tools when determining both sarcopenia
and myosteatosis did not exceed 0.6. Total MST score
demonstrated the largest AUC for pre-cachexia (AUC = 0.677,
P = 0.002), while MUST yielded the largest for CC
(AUC = 0.816, P < 0.001); however, it did not demonstrate
diagnostic reliability for the detection of the cases of CC
diagnosed by CT scan alone. Of those diagnosed with CC by
CT alone, 58% were given a MUST score of 0, 40% were given
a score of 1, and 2% were given a score of 2. In terms of the
ability of tools to detect the presence of any of the malnour-
ished states of interest, MUST demonstrated the largest AUC
(0.71, P < 0.001).
Survival analysis
In total, 287 deaths occurred. Overall, the median follow-up
time was 12.2 months (interquartile range 6.6–26.1 months),
with a median follow-up for censored cases of 19.9 months
(interquartile range 8.2–32.2 months). The predictive value
of sarcopenia, myosteatosis, pre-cachexia, CC, MUST score,
MST score, and NRI score on survival were all individually
assessed; in each case, controlling for factors that were either
signiﬁcant on a univariate level or known to impact upon
prognosis, speciﬁcally age, sex, performance status, BMI,
disease stage, and disease site. Controlling for these factors,
myosteatosis (HR 1.6, 95% conﬁdence interval: 1.2–2.1,
P < 0.001) and NRI score remained signiﬁcant predictors of
survival on a multivariate level. NRI was the strongest
signiﬁcant predictor, with those having a score < 97.5 found
to be at an increased risk of mortality (HR 1.8, 95%
conﬁdence interval: 1.2–2.8, P = 0.007) (median survival of
10 months for those with a NRI score of <97.5 vs. 30 months
for those with a NRI score of >100, P < 0.001). A
Kaplan–Meier curve comparing the survival (in days) of those
with an NRI ≥97.5 vs. those with an NRI < 97.5 is displayed in
Figure 3.
Discussion
Cancer-related malnutrition is an umbrella term used to
describe the range of adverse nutritional conditions that
occur in the oncology setting and can encompass a number Ta
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of nutritional or body composition disorders. Involuntary
weight loss can occur in isolation, as a result of a negative
energy balance, or can be a symptom or manifestation of a
cachexia–anorexia syndrome.9 The deﬁnition of CC is complex,
as there are a number of deﬁnitions available to characterize
the wasting syndrome in general disease. The primary
concepts that form diagnostic criterion include involuntary
weight loss, reduced nutritional intake, presence of systemic
inﬂammation, anorexia, diminished physical function, reduced
musclemass, and reducedmuscle strength.34–36 CC represents
a spectrum, from pre-cachexia to refractory cachexia, and the
success of a nutritional intervention depends upon the point
at which an intervention is implemented.9
Although starvation and CC both yield weight loss, the
proportion of muscle and fat mass lost is different depending
on the primary driver of the weight loss, i.e. negative energy
balance or systemic inﬂammation, with muscle degradation
promoted in states of inﬂammation.37 Sarcopenia refers to
a low relative muscle mass and is deﬁned as appendicular
skeletal muscle mass (kg)/height2 (m2) less than 2 SD below
the mean of a healthy, young reference group.38 Muscle
quantity cannot be considered in isolation and also needs
to be assessed in the context of muscle quality. Myosteatosis,
a condition characterized by low muscle density secondary to
increased levels of intermuscular and intramuscular fat, has
come to the fore in recent years as an area of interest in
the oncology setting.39
Assessment of malnutrition should no longer focus primar-
ily on weight loss or BMI, as muscle quality and quantity
continue to emerge as important predictors of treatment tol-
erance and clinical outcome. Sarcopenia and myosteatosis
have been signiﬁcantly associated with a range of adverse
outcomes including increased rate of post-operative compli-
cations,10,11,40–42 longer length of hospital stay,41,43 30-day
post-operative mortality and in-hospital mortality,44 and
dose-limiting toxicities.5–8,45–50 In addition, the conditions
have been demonstrated as independent predictors of
reduced overall survival.18,51–64 The situation is further
complicated by the obesity epidemic that has been progres-
sively worsening in recent times. Adiposity is an established
risk factor for cancer, and recent studies have reported that
between 40% and 60% of cancer patients are overweight or
obese, even in the setting of metastatic disease.4,17,18,65,66
Irrespective of BMI, hidden malnutrition can be present,
yields adverse clinical consequences, and needs to be identi-
ﬁed and addressed.18
Although treatment of cancer-related malnutrition is often
treated with a degree of nihilism; early, targeted, multimodal
nutritional treatment is essential and yields tangible clinical
beneﬁts.67,68 Lack of nutritional treatment not only impacts
on clinical outcomes and prognosis but it also causes signiﬁ-
cant distress for patients69 and their family members and
carers.70
Although CT assessment is the gold standard method of
body composition analysis in oncology patients, widespread
application in the clinical setting is not feasible because of
resource and stafﬁng constraints. Nutritional screening is
critically important in order to identify patients in greatest
need of nutritional therapy. This is further emphasized by
recent ﬁndings that highlight the strong association between
nutritional screening and survival prediction in oncology
populations.71 In the USA, universal screening and assess-
ment of malnutrition in hospitalized patients is mandatory
within 24 h of admission.23,24
Figure 3 Kaplan–Meier curve comparing the survival of those with a Nutritional Risk Index (NRI) ≥ 97.5 vs. those with a NRI < 97.5.
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While an abundance of screening tools are available, a few
have been developed to capture abnormal body composition
phenotypes, and to date, there is no consensus on the
optimal tool to be employed in the oncology setting. A recent
study constructed a ﬁve step questionnaire to predict
patients at risk of sarcopenia speciﬁcally72; however, little
research has been performed to assess whether tools
currently in use are adequately capturing patients with
nutrition-related syndromes that place them at a higher risk
of adverse clinical outcomes. It has been previously
suggested that the latter should be the priority for further
research, rather than the development of new screening
tools in an already saturated setting.73
To our knowledge, this is the ﬁrst study of its kind to
explore what proportion of patients with abnormal body
composition phenotypes are being detected by commonly
used nutritional screening tools. As these tools were not
devised speciﬁcally for the detection of sarcopenia,
myosteatosis, or CC, validation is most appropriately
performed against a full nutritional assessment. These tools
are widely employed in oncology patients; however, and
therefore, it is important to examine their capacity in this
setting speciﬁcally and to assess their ability to detect condi-
tions that are so inﬂuential in this patient population.
Malnutrition was found to be very high in this large cohort,
with abnormal body composition phenotypes highly
prevalent, despite the high level of overweight and obesity
recorded. The majority of patients had a BMI in the
overweight/obese category at the time of screening.
Although high rates of muscle wasting was detected using
CT analysis, excessive adiposity appeared to mask this
wasting and undernutrition. A large portion of patients that
met the criteria for CC (37.2%) maintained a stable overall
body weight yet had changes in muscle and fat mass that
was only detectable using CT analysis. None of the screening
tools assessed demonstrated a complimentary balance of
sensitivity and speciﬁcity for the detection of the abnormal
body composition phenotypes; however, a tool that
generates a low AUC can still be useful in certain clinical
settings. MUST was the most effective in detecting CC;
however, this is unsurprising, as the diagnosis of CC is based
upon the same parameters included in the MUST tool, i.e.
weight loss and low BMI. Interestingly, 38% of CC cases in this
cohort were diagnosed using CT scan alone and were not
identiﬁable using the BMI or weight loss elements of the
diagnostic criteria. No screening tool had the ability to over-
come this deﬁcit. Because of the increasing rates of
overweight/obesity in this patient population, it could be
proposed that less importance should be placed on BMI,
because as shown, patients with a healthy, overweight, or
obese BMI can suffer from severe levels of malnutrition.
Incorporating a BMI score may ultimately place too much
emphasis on body weight and allow hidden malnutrition to
go undetected.
The NRI tool was highly sensitive; however, a lack of spec-
iﬁcity reduced its overall accuracy. It could be argued that the
cost incurred by referring patients for a secondary nutrition
assessment would be far less than the cost of undetected
malnutrition in the oncology setting or that the tool may
have potential use as the ﬁrst stage of a nutritional screening
programme. Another vital issue that needs consideration is
that each malnourished state is not necessarily mutually
exclusive; therefore, it cannot be fully determined whether
the ‘false positives’ produced when assessing one form of
malnutrition are being generated on the basis of another
form of malnutrition and therefore in reality are not actually
‘false’. We explored this theory by investigating the ability of
the screening tools to detect the presence of any of the
following conditions: sarcopenia, myosteatosis, pre-cachexia,
and CC. In this assessment, we found the NRI to have the best
overall accuracy (74.7%) in highlighting patients who have at
least one of the conditions in question.
Most notably, myosteatosis and NRI score ≤ 97.5 were
established as prognostic indicators, independent of
confounding factors. NRI was the strongest predictor, with pa-
tients categorized as being at moderate to severe nutritional
risk by the tool, almost twice as likely to die (HR 1.8, conﬁ-
dence interval: 1.2–2.8, P = 0.007) and died on average three
times earlier than nutritionally well counterparts (median sur-
vival of 10 months vs. 30 months, P < 0.001). NRI may have
the ability to directly predict a primary endpoint, survival,
while cutting out the intermediary stages of identifying
nutritional conditions, which have previously been shown to
predict survival. The tool therefore could potentially prove
useful for the identiﬁcation of nutritionally vulnerable
patients at risk of reduced survival, at an early stage, before
a refractory state manifests, and when nutritional interven-
tion is most effective.9,74 Effective, timely screening is essen-
tial in order to allow for appropriate referral to a dietitian
for a thorough nutritional assessment and targeted treatment
plan to address patients’ speciﬁc nutritional inadequacies.
Conclusions
Malnutrition is highly prevalent in the Irish ambulatory
oncology setting. Excessive adiposity appears to mask the
muscle wasting and undernutrition that was present during
screening, with vast misclassiﬁcation of nutritionally vulnera-
ble patients by commonly used nutritional screening tools.
No tool assessed in the study demonstrated a complimentary
balance of sensitivity and speciﬁcity for the detection of the
abnormal body composition phenotypes identiﬁable by CT
analysis. NRI was the strongest independent predictor of
shorter survival and demonstrated an ability to directly
predict the primary endpoint of interest, reduced survival.
CT scans play a unique role because of their availability;
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however, automation of body composition analysis is required
to truly exploit the use of CTs in the clinical oncology setting.
Until that is available, an effective method of grading patient’s
nutritional risk is critically required in order to ensure the most
nutritionally vulnerable patients, including those with hidden
muscle wasting, are referred for extensive nutritional assess-
ment and targeted nutritional treatment.
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